Trial Profile
A multi-center, investigator-blinded, randomized, 12-month, parallel-group, non-inferiority study to compare the efficacy of 1.6 to 2.4 g Asacol (Rm) therapy QD versus divided dose (BID) in the maintenance of remission of ulcerative colitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms QDIEM
- Sponsors Procter & Gamble
- 18 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Mar 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 24 Mar 2010 Warner Chilcott added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.